Vesugen
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Vesugen is a synthetic tripeptide – lysine, glutamic acid, aspartic acid – derived from the peptide bioregulator class pioneered at the St. Petersburg Institute of Bioregulation and Gerontology. Its proposed mechanism is epigenetic rather than receptor-agonist in the classical sense: the peptide is thought to interact directly with chromatin-associated proteins and gene promoter regions, modulating transcription of genes governing vascular cell turnover, extracellular matrix synthesis, and endothelial homeostasis. The literature describes it as a tissue-specific signal – one the vascular system appears already primed to receive.
Chromatin binding is the proposed entry point, with Vesugen’s Lys-Glu-Asp sequence reported to interact with H1 histone subtypes and alter local condensation. The mechanism is framed as epigenetic rather than receptor-mediated in the published preclinical literature.
Endothelial survival is the primary cellular output observed in vitro, particularly under oxidative stress. In HUVEC models, KED has been reported to reduce apoptotic markers, increase Bcl-2 family protein expression, and upregulate transcripts associated with vascular maintenance.
Matrix remodeling appears to be the connective tissue correlate of this signal in fibroblasts and smooth muscle cells. Reported shifts in MMP/TIMP balance and increases in hydroxyproline incorporation suggest a matrix-preserving effect, though translation to arterial wall compliance remains unestablished.
Telomerase modulation is the most longevity-adjacent claim associated with KED. Evidence from the Khavinson group suggests possible effects on telomerase expression in somatic cells, but the data remain limited to in vitro and animal models.
What we observe
Changes researchers saw in vascular health markers
The outcomes attributed to Vesugen cluster around endothelial longevity, vascular structural integrity, and connective tissue preservation. Findings are consistent in direction across cell culture and animal studies, though effect sizes are modest. Independent replication at scale has not yet occurred.
01
Endothelial Viability
02
Collagen Synthesis
03
MMP TIMP Balance
04
Chromatin Access
05
Vascular Aging Markers
06
Telomerase Activity
Evidence
What research says so far
The evidence base originates primarily from the St. Petersburg Institute of Bioregulation and Gerontology. Studies span cell culture, rodent models, and limited clinical observation; methodologies are heterogeneous and independent replication is absent. The findings are presented as the available literature, not settled consensus.
Tripeptide Lys-Glu-Asp Stimulates Expression of Vascular Endothelial Growth Factor in Human Endothelial Cells
Cell culture experiments demonstrated that KED at concentrations of 0.01–10 ng/mL significantly increased VEGF mRNA expression in HUVEC lines under normoxic conditions, with concurrent reductions in caspase-3 activation markers. The authors proposed a direct chromatin-mediated transcriptional mechanism rather than a surface receptor pathway.
Effect of Peptide Bioregulator KED on Vascular Wall Morphology in Aged Wistar Rats
Aged Wistar rats (22–24 months) administered subcutaneous KED at 1 µg/kg daily for 30 days showed statistically significant reductions in intima-media thickness of the thoracic aorta compared to saline controls. eNOS immunoreactivity was preserved in the KED group relative to age-matched controls, suggesting maintained endothelial synthetic capacity.
Histone H1 Binding Affinity of Short Peptide Bioregulators and Implications for Chromatin-Mediated Gene Regulation
Molecular docking and fluorescence polarization assays confirmed direct binding of KED to histone H1.3 and H1.4 subtypes, with dissociation constants in the low micromolar range. Chromatin immunoprecipitation (ChIP) assays in treated fibroblast lines showed increased accessibility at promoter regions of COL4A1 and VEGFA, supporting the proposed epigenetic mechanism of action.
From lyophilized powder to a usable solution.
Peptide
20 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
6.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 500–2000 mcg once daily (gradual titration)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
- Avoid freeze–thaw cycles.
- Use amber or opaque vials where possible; KED, like most short peptides, is susceptible to UV-mediated degradation.
- Label each vial with reconstitution date and concentration; discard any solution showing particulate matter or discoloration.
Side effects
What members describe
- Injection site reactions - mild erythema or transient discomfort - are the most commonly noted adverse events in the limited clinical observation literature.
- No systemic toxicity has been reported at doses used in published animal studies; the therapeutic index appears wide in rodent models.
- Headache and transient fatigue have been anecdotally noted in human observational reports; causal attribution is uncertain.
- Given the proposed epigenetic mechanism, theoretical concerns about off-target transcriptional effects exist; long-term safety data in humans are absent.
- No immunogenic reactions have been formally reported, though systematic immunogenicity studies in humans have not been conducted.
Contradictions
Reasons to abstain
- Active malignancy or personal history of vascular neoplasm: the pro-proliferative endothelial signaling associated with VEGF upregulation warrants caution.
- Pregnancy and lactation: no safety data exist; use is not supported by any published evidence in these populations.
- Known hypersensitivity to any component of the formulation or to related tripeptide bioregulators.
- Concurrent use of anticoagulant or antiplatelet therapy: theoretical interactions with vascular remodeling pathways have not been formally studied.
- Pediatric populations: no data; the peptide bioregulator class has been studied exclusively in adult and aged-adult contexts.
Synergies
Good partners for Vesugen
Vesugen’s proposed activity – endothelial preservation, matrix remodeling, epigenetic vascular signaling – positions it within a broader curriculum of peptides and compounds studied for cardiovascular and connective tissue longevity. The combinations below reflect thematic and mechanistic adjacency as described in the literature; they are not clinical protocols.
FAQ
Your questions, patiently answered
Vesugen (KED) is tissue-specific in its proposed targeting – the published literature consistently associates it with vascular endothelium and connective tissue, distinguishing it from Epithalon (broad cellular aging), Vilon (immune system), or Cortagen (nervous system). The specificity is thought to arise from the tripeptide sequence itself, which may preferentially bind chromatin-associated proteins expressed in vascular cell lineages.
It is proposed and supported by biochemical binding data, but not yet confirmed by independent large-scale studies. The histone H1 binding affinity reported in the 2017 Journal of Peptide Science paper is the strongest mechanistic evidence available. Chromatin immunoprecipitation data are promising but have not been replicated outside the originating laboratory. The mechanism should be read as a well-articulated hypothesis with supporting evidence, not a settled fact.
Formal randomized controlled trials in humans have not been published in indexed international journals. The clinical observation literature originates primarily from Russian gerontological practice, where peptide bioregulators have been used under institutional protocols for decades. This body of evidence is real but methodologically limited by Western clinical trial standards. Independent replication is needed.
This is a legitimate and unresolved concern. VEGF is a potent angiogenic signal, and its upregulation in the context of occult or established malignancy could theoretically support tumor vascularization. The published literature does not report oncogenic outcomes in animal studies, but long-term human safety data are absent. Individuals with active malignancy or significant cancer history should treat this as a meaningful contraindication, not a theoretical footnote.
The connection is preliminary. Khavinson’s group has published data suggesting that short peptide bioregulators, including KED, may influence telomerase activity in cultured somatic cells. If confirmed, this would place Vesugen within the broader conversation about peptide-mediated cellular aging – a conversation that Epithalon has occupied more prominently. The telomere data for Vesugen specifically are sparse and should be treated as hypothesis-generating.
Correct. Aeterna does not prescribe, dispense, or sell. Our role is educational: to translate the available literature into a coherent framework for those who engage with it professionally. Sourcing decisions for research use belong to qualified investigators working within appropriate institutional and regulatory frameworks. Our vendor directory lists suppliers who meet our documentation and purity standards; it is a reference, not an endorsement.
In the same family
Adjacent entries in the curriculum of vascular and cellular aging.
Sourcing · Independently verified
When you're ready, source thoughtfully.